loading page

Community analysis of large-scale molecular dynamics simulations elucidated dynamics-driven allostery in Tyrosine kinase 2
  • Metaxia Vlassi,
  • Nastazia Lesgidou
Metaxia Vlassi
Ethniko Kentro Ereunas Physikon Epistemon Demokritos

Corresponding Author:[email protected]

Author Profile
Nastazia Lesgidou
Ethniko Kentro Ereunas Physikon Epistemon Demokritos
Author Profile


TYK2 is a non-receptor tyrosine kinase, member of the Janus kinases (JAK), with a central role in several diseases, including cancer. The JAKs’ catalytic domains (KD) are highly conserved, yet the isolated TYK2-KD exhibits unique specificities. In a previous work, using molecular dynamics (MD) simulations of a catalytically-impaired TYK2-KD variant (P1104A) we found that this amino-acid change of its JAK-characteristic insert (αFG), acts at the dynamics level. Given that structural dynamics is key to allosteric activation of protein kinases, in this study we applied a long-scale MD simulation and investigated an active TYK2-KD form in the presence of adenosine 5’-triphosphate and one magnesium ion that represents a dynamic and crucial step of the catalytic cycle, in other protein kinases. Community analysis of the MD trajectory shed light, for the first time, on the dynamic profile and dynamics-driven allosteric communications within the TYK2-KD during activation and revealed that αFG and amino-acids P1104, P1105 and I1112 in particular, hold a pivotal role and act synergistically with a dynamically coupled communication network of amino-acids serving intra-KD signaling for allosteric regulation of TYK2 activity. Corroborating our findings, most of the identified amino-acids are associated with cancer-related missense/splice-site mutations of the Tyk2 gene. We propose that the conformational dynamics at this step of the catalytic cycle, coordinated by αFG, underlies TYK2-unique substrate recognition and accounts for its distinct specificity. In total, this work adds to knowledge towards an in-depth understanding of TYK2 activation and may be valuable towards a rational design of allosteric TYK2-specific inhibitors.
17 Jul 2023Submitted to PROTEINS: Structure, Function, and Bioinformatics
18 Jul 2023Submission Checks Completed
18 Jul 2023Assigned to Editor
18 Jul 2023Review(s) Completed, Editorial Evaluation Pending
21 Jul 2023Reviewer(s) Assigned
07 Sep 2023Editorial Decision: Revise Major
14 Oct 20231st Revision Received
14 Oct 2023Submission Checks Completed
14 Oct 2023Assigned to Editor
14 Oct 2023Review(s) Completed, Editorial Evaluation Pending
14 Oct 2023Reviewer(s) Assigned
24 Oct 2023Editorial Decision: Accept